Insulin Resistance Market Outlook, Trends And Future Opportunities (2023-2030)

Insulin Resistance Market Outlook, Trends And Future Opportunities (2023-2030)

Insulin Resistance Market, By Drug Class (Biguanides, Thiazolidinediones, DPP-4 Inhibitors, SGLT-2 Inhibitors, GLP-1 Receptor Agonists, Others), By Route of Administration (Oral, Injectable, Inhalable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Diabetes Clinics/Centers), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Oct 2023
  • Report ID: IDA50
  • Region: Global
  • Format: PDF/EXCEL

Table Of Contents

  • Chapter 1. Research Methodology and Scope
    • Market Segmentation and Scope
    • Regional Coverage
    • Objectives
    • Research Methodology
  • Chapter 2. Executive Summary
    • Market Landscape
    • Market Size & Forecast
    • Competitive Landscape
  • Chapter 3. Insulin Resistance Market: By Drug Class Segment Market Trends, Size, and Future Outlook
    • By Drug Class Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • By Drug Class Segment Definitions, Technology Landscape
    • By Drug Class Segment Market Drivers
      • Product Launches
      • Technology Launches
    • By Drug Class Segment Market Restraints
      • Medication Cost
      • Low Access to Medications
  • Chapter 4. Insulin Resistance Market: By Route of Administration Segment Market Trends, Size, and Future Outlook
    • By Route of Administration Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • By Route of Administration Segment Definitions, Technology Landscape
    • By Route of Administration Segment Market Drivers
    • By Route of Administration Segment Market Restraints
  • Chapter 5. Insulin Resistance Market: By Distribution Channel Segment Market Trends, Size, and Future Outlook
    • By Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • By Distribution Channel Segment Definitions, Technology Landscape
    • By Distribution Channel Segment Market Drivers
    • By Distribution Channel Segment Market Restraints
  • Chapter 6. Insulin Resistance Market: Regional Market Trends, Size, and Future Outlook
    • North America
      • North America Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
      • North America Definitions, Technology Landscape
      • North America Market Drivers
      • North America Market Restraints
      • Country Outlook
        • U.S.
        • Canada
    • Europe
      • Europe Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
      • Europe Definitions, Technology Landscape
      • Europe Market Drivers
      • Europe Market Restraints
      • Country Outlook
        • UK
        • Germany
        • Italy
        • France
        • Spain
        • Rest of Europe
    • Asia Pacific
      • Asia Pacific Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
      • Asia Pacific Definitions, Technology Landscape
      • Asia Pacific Market Drivers
      • Asia Pacific Market Restraints
      • Country Outlook
        • China
        • Japan
        • India
        • South Korea
        • Australia
        • ASEAN
        • Rest of APAC
    • Latin America
      • Latin America Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
      • Latin America Definitions, Technology Landscape
      • Latin America Market Drivers
      • Latin America Market Restraints
      • Country Outlook
        • Brazil
        • Argentina
        • Colombia
        • Rest of LATAM
    • Middle East & Africa
      • Middle East & Africa Region Market Size (US$), CAGR (%), and Forecast (2022-2030)
      • Middle East & Africa Definitions, Technology Landscape
      • Middle East & Africa Market Drivers
      • Middle East & Africa Market Restraints
      • Country Outlook
        • Nigeria
        • Saudi Arabia
        • GCC
        • Rest of the Countries
  • Chapter 7. Insulin Resistance Market: Competitive Landscape
    • Novo Nordisk
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Sanofi
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Eli Lilly
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • AstraZeneca
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Johnson & Johnson
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Abbott Laboratories
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Merck
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • GSK
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Pfizer
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Novartis
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Boehringer Ingelheim
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Takeda
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Biocon
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Cipla
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
    • Sun Pharma
      • Company Overview
      • Financial Outlook
      • Product Portfolio
      • Strategies
  • Research Methodology
    • Primary Research
    • Secondary Research
    • Assumptions
    • IDataAcumen Analysis
    • Paid Databases
  • Appendix
  • About Us

Frequently Asked Questions

The Insulin Resistance Market is valued at USD 23.4 billion in 2023. current market size of the genital herpes industry is estimated at around US$ 5.2 billion in 2023.

Rising prevalence of diabetes and obesity, development of novel drugs and devices, favorable policies, technological integration, improving diagnosis, patient awareness programs.

Stringent regulatory requirements, long product development timelines, pricing pressure, side effects, limited awareness in developing regions.

Biguanides drugs like metformin are the leading segment owing to widespread use as first line of treatment.

Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Abbott, Roche, Merck, Medtronic, J&J.

The market is projected to reach USD 32.8 billion by 2030 from USD 23.4 billion in 2023, growing at a CAGR of 4.9% during the forecast period.

Rising prevalence of diabetes and obesity, unhealthy lifestyles, advancing pharmaceutical R&D, favorable reimbursement policies, integration of digital technology.